Cassava laying off one-third of staff to curb expenses
by
Contributor since / Followers
Contributor since / Followers
1 week ago
BrianAJackson Cassava Sciences (NASDAQ:SAVA) is laying off 33% of its workforce — 10 employees —
SAVA
Cassava Sciences: REFOCUS Unlikely To Save Simufilam, Careful Development Needed
by Biotech Beast
Contributor since 2015 / 8175 Followers
Contributor since 2015 / 8175 Followers
2 months ago
Summary: Cassava Sciences’ phase 3 RETHINK study of simufilam in Alzheimer’s disease was not a
Cassava Sciences: Probably The End Of The Saga
by Tejo Strategy Investing
Contributor since 2024 / 93 Followers
Contributor since 2024 / 93 Followers
2 months ago
Summary: Cassava Sciences’ Phase 3 trial for Alzheimer’s failed to meet primary or secondary endpoints,
Cassava Sciences: Phase 3 Alzheimer’s Drug Fail The Final Nail In The Coffin
by Edmund Ingham
Contributor since 2018 / 12771 Followers
Contributor since 2018 / 12771 Followers
2 months ago
Summary: Cassava Sciences’ Alzheimer’s drug simufilam failed to meet primary, secondary, and exploratory endpoints in
Cassava Sciences Faces Reality After Simufilam’s Phase 3 Failure
by Stephen Ayers
Contributor since 2017 / 7750 Followers
Contributor since 2017 / 7750 Followers
2 months ago
Summary: Cassava Sciences’ Alzheimer’s drug simufilam failed its Phase 3 trial, causing the stock to
What’s left in Cassava after Phase 3 setback for Alzheimer’s drug
by
Contributor since / Followers
Contributor since / Followers
2 months ago
Eoneren/E+ via Getty Images Cassava Sciences (NASDAQ:SAVA) crashed nearly 84% following a late-stage trial setback
Cassava plummets 86% as simufilam phase 3 Alzheimer’s trial misses endpoints
by
Contributor since / Followers
Contributor since / Followers
2 months ago
travellinglight Cassava Sciences (NASDAQ:SAVA) stock has plummeted ~86% after announcing that Alzheimer’s disease candidate simufilam
Cassava taps Freda Nassif as chief commercial officer as simufilam Phase 3 readout nears
by
Contributor since / Followers
Contributor since / Followers
2 months ago
travellinglight/iStock via Getty Images Cassava Sciences (NASDAQ:SAVA) has tapped Freda Nassif as chief commercial officer,
Cassava Sciences updates on Phase 3 Alzheimer’s trial ahead of key readout
by
Contributor since / Followers
Contributor since / Followers
2 months ago
travellinglight/iStock via Getty Images A federal registry on clinical trials indicated on Friday that Cassava
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer’s Disease
by Lane Simonian
Contributor since 2015 / 2525 Followers
Contributor since 2015 / 2525 Followers
2 months ago
Summary: Panax ginseng shows the highest effectiveness in treating Alzheimer’s because it inhibits nitro-oxidative stress,